Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01BB04 CLADRIBINUM SOL. INJ. 2 mg/ml

LITAK 2 mg/ml 2 mg/ml LIPOMED GMBH

________________________________________________________________________________

______________________________________________________________________________

| 719 |L01BB05| FLUDARABINUM**** | Protocol: L048C |

|_______|_______|____________________________________________|_________________|
NOTĂ:

Tratamentul pacienţilor cu leucemie limfocitară cronică cu celule B (LLC), cu rezervă medulară suficientă, care nu au răspuns la tratament sau a căror boală a avansat în timpul tratamentului cu o schemă conţinând cel puţin un agent alchilant standard sau ulterior acestuia.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01BB05 FLUDARABINUM COMPR. FILM. 10 mg

FLUDARA(R) 0RAL 10 mg SCHERING AG

________________________________________________________________________________

______________________________________________________________________________

| 720 |L01BC01| CYTARABINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01BC01 CYTARABINUM PULB. + SOLV. PT. SOL. 100 mg

INJ.

CYTOSAR(TM) 100 mg 100 mg PFIZER EUROPE MA EEIG

L01BC01 CYTARABINUM SOL. INJ. 20 mg/ml

ALEXAN 20 mg/ml 20 mg/ml EBEWE PHARMA GMBH NFG. KG

L01BC01 CYTARABINUM SUSP. INJ. 50 mg

DEPOCYTE 50 mg 50 mg SKYEPHARMKA PLC

L01BC01 CYTARABINUM SOL. INJ. 50 mg/ml

ALEXAN 50 mg/ml 50 mg/ml EBEWE PHARMA GMBH NFG. KG

________________________________________________________________________________
______________________________________________________________________________

| 721 |L01BC02| FLUOROURACILUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01BC02 FLUOROURACILUM SOL. PERF./INJ. 250 mg/5 ml

FLUOROSINDAN 250 mg/5 ml 250 mg/5 ml ACTAVIS S.R.L.
L01BC02 FLUOROURACILUM UNGUENT 50 mg/g

EFUDIX 50 mg/g ICN HUNGARY CO. LTD.

L01BC02 FLUOROURACILUM CONC. PT. SOL. 50 mg/ml

INJ./PERF.

5 - FLUOROURACIL 50 mg/ml EBEWE PHARMA GMBH NFG. KG

EBEWE 50 mg/ml

________________________________________________________________________________
______________________________________________________________________________

| 722 |L01BC05| GEMCITABINUM** | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Terapia asociată a cancerului mamar avansat cu